Elicio Therapeutics Inc. (ELTX)vsRevolution Medicines Inc (RVMD)
ELTX
Elicio Therapeutics Inc.
$2.89
-2.03%
HEALTHCARE · Cap: $78.79M
RVMD
Revolution Medicines Inc
$192.17
+6.22%
HEALTHCARE · Cap: $39.58B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
ELTX
Avoid17
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ELTX
The strongest argument for ELTX centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ELTX
The primary concerns for ELTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
ELTX carries more volatility with a beta of 1.78 — expect wider price swings.
ELTX is growing revenue faster at 0.0% — sustainability is the question.
ELTX generates stronger free cash flow (-12M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 17/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elicio Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002, leverages a proprietary Amphiphilic TLR9 Agonist to elicit robust immune responses against various cancer types, aiming to enhance patient outcomes. By concentrating on personalized cancer vaccines and groundbreaking immunotherapeutic approaches, Elicio Therapeutics is uniquely positioned to tackle significant unmet clinical needs in oncology, while advancing its compelling pipeline through rigorous clinical trials that could redefine the standard of cancer care.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?